SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

ABBV-706

ABBV·AbbVie Inc.
MIXED
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Likely several years away. The Phase 3 trial started recruiting in July 2026 with an estimated 53-month duration, so a potential regulatory filing would be no earlier than 2028-2029 barring accelerated approval based on Phase 2 data.
Why 4/10
ABBV-706 has no scheduled PDUFA date or pivotal readout within the next ~12 months; its Phase 3 trial (NCT07365241) began recruiting in July 2026 with an estimated 53-month duration. The drug is one of many pipeline assets at a large-cap pharma, so even a positive future readout would have a modest impact on AbbVie's stock price.
Actionable Insight MIXED

The next hard catalyst for ABBV-706 is the Phase 3 (NCT07365241) topline readout, but that is likely 2-3 years away given the trial started recruiting in July 2026. Watch for interim analysis announcements and any updates on the Phase 2 SEZanne frontline combination trial. For now, ABBV-706 is a promising but early-stage asset within AbbVie's broad pipeline, not a near-term binary event for the stock.

Price Chart

Loading chart...

Executive Summary

ABBV-706 is AbbVie's investigational antibody-drug conjugate (ADC) targeting the SEZ6 protein, being developed primarily for relapsed/refractory small cell lung cancer (SCLC). Phase 1 data presented at ASCO and ESMO 2026 showed a 56% objective response rate at the recommended Phase 3 dose (1.8 mg/kg) and 82% ORR in second-line patients, with median overall survival of 12.4 months. The drug received FDA Orphan Drug Designation for SCLC in October 2024. A global Phase 3 trial (NCT07365241) comparing ABBV-706 against standard of care began recruiting in July 2026 with a target of 531 patients, and a Phase 2 SEZanne trial is evaluating ABBV-706 plus atezolizumab in frontline extensive-stage SCLC. However, ABBV-706 faces strong competition from Amgen's already-approved Imdelltra (tarlatamab), which recently posted Phase 3 data showing a 58% reduction in death risk. As one of many pipeline assets at a ~$520B large-cap pharma, ABBV-706 has no near-term binary catalyst for AbbVie's stock.

How It Works

ABBV-706 is an antibody-drug conjugate (ADC), a type of targeted cancer therapy. It works like a guided missile: one part of the drug (the antibody) seeks out and binds to a protein called SEZ6 found on the surface of small cell lung cancer and certain other tumor cells. Once attached, the drug releases a chemotherapy payload (a topoisomerase 1 inhibitor) directly inside the cancer cell, killing it while largely sparing healthy cells. The drug-to-antibody ratio is 6, meaning each antibody carries six payload molecules.

Trial Status

A global Phase 3 randomized trial (NCT07365241) comparing ABBV-706 against standard of care (topotecan, lurbinectedin, or amrubicin) in relapsed/refractory SCLC began recruiting in July 2026, targeting 531 patients across ~175 sites in 10 countries. A Phase 2 SEZanne trial (NCT07155174) is evaluating ABBV-706 combined with atezolizumab in frontline extensive-stage SCLC. Phase 1 monotherapy data (NCT05599984) has been published in Nature Medicine and presented at ASCO and ESMO 2026.

The Two-Sided Case

▲ Bull Case4
Phase 1 data at the recommended Phase 3 dose showed a 56% objective response rate across all R/R SCLC patients and an 82% ORR in second-line patients, with median overall survival of 12.4 months (14.3 months in 2L), which is highly competitive in this difficult-to-treat cancer.
ABBV-706 received FDA Orphan Drug Designation for SCLC in October 2024, providing 7-year market exclusivity upon approval and development incentives.
The SEZ6 target is distinct from DLL3 (targeted by Amgen's Imdelltra), potentially offering a differentiated mechanism and the possibility of combination or sequential use.
AbbVie is running both a Phase 3 trial in relapsed/refractory SCLC and a Phase 2 SEZanne trial combining ABBV-706 with atezolizumab in frontline ES-SCLC, expanding the addressable market opportunity.
▼ Bear Case4
Competition is intensifying: Amgen's Imdelltra (tarlatamab-dlle) is already FDA-approved for 2L ES-SCLC and recently posted Phase 3 DeLLphi-305 data showing a 58% reduction in death risk when combined with Imfinzi in frontline maintenance, setting a high bar.
Phase 1 data showed 93% any-grade treatment-related adverse events and 61% grade 3 or higher TRAEs, indicating meaningful toxicity that could complicate the Phase 3 profile versus standard of care.
The Phase 3 trial (NCT07365241) only started recruiting in July 2026 with a 53-month estimated duration, meaning a readout is years away and there is no near-term binary catalyst.
ABBV-706 is one of many pipeline assets at AbbVie; even a positive readout would have a modest impact on the stock given AbbVie's ~$520B market cap and diversified revenue base (Humira, Skyrizi, Rinvoq, etc.).

Upcoming Catalysts

  • Phase 3 (NCT07365241) interim or final topline readout, likely 2-3 years out
  • Phase 2 SEZanne trial (ABBV-706 + atezolizumab in frontline ES-SCLC) updates
  • Potential regulatory filing if AbbVie pursues accelerated approval based on Phase 1/2 data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 10

Hover a chip for the title
1 nature.com2 varese-group.com3 ascopubs.org4 news.abbvie.com5 clinicaltrials.gov6 trial.medpath.com7 ecancer.org8 biospace.com9 ascopubs.org10 trialticker.com